Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma

Journal of Immunology

Volumn 175, Issue 6, 2005, Pages 4137-4147

  Straathof, Karin C ^a   Leen, Ann M ^a   Buza, Elizabeth L ^a   Taylor, Graham ^b   Huls, M Helen ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a   Bollard, Catherine M ^a,c  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA A0204 ANTIGEN; HLA A0206 ANTIGEN; HLA A29 ANTIGEN; HLA A68 ANTIGEN; HLA B ANTIGEN; HLA B1402 ANTIGEN; HLA B27 ANTIGEN; HLA B3501 ANTIGEN; HLA B53 ANTIGEN; HLA DR ANTIGEN; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; PEPTIDE LIBRARY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; GENE SEQUENCE; GENETIC CONSERVATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOMA; NASOPHARYNX CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; T LYMPHOCYTE; VACCINATION; VIRUS STRAIN;

EID: 24744453933     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.6.4137     Document Type: Article

References (55)

1. Niedobitek, G. 2000. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol. Pathol. 53: 248-254.
2. Solomides, C. C., A. S. Miller, R. A. Christman, J. Talwar, and H. Simpkins. 2002. Lymphomas of the oral cavity: histology, immunologic type, and incidence of Epstein-Barr virus infection. Hum. Pathol. 33: 153-157.
3. Herbst, H., F. Dallenbach, M. Hummel, G. Niedobitek, S. Pileri, N. Muller-Lantzsch, and H. Stein. 1991. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc. Natl. Acad. Sci. USA 88: 4766-4770.
4. Pallesen, G., S. J. Hamilton-Dutoit, M. Rowe, and L. S. Young. 1991. Expression of Epstein-Barr virus latent gene products in tumor cells of Hodgkin's disease. Lancet 337: 320-322.
5. Heslop, H. E., C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney. 1996. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2: 551-555.
6. Rooney, C. M., C. A. Smith, C. Y. Ng, S. K. Loftin, J. W. Sixbey, Y. Gan, D. K. Srivastava, L. C. Bowman, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92: 1549-1555.
7. + T lymphocytes. J. Exp. Med 199: 459-470.
8. Lee, S. P., J. M. Brooks, H. Al Jarrah, W. A. Thomas, T. A. Haigh, G. S. Taylor, S. Humme, A. Schepers, W. Hammerschmidt, J. L. Yates, et al. 2004. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J. Exp. Med. 199: 1409-1420.
9. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J. Exp. Med. 199: 1421-1431.
10. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7: 791-802.
11. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375: 685-688.
12. Yin, Y., B. Manoury, and R. Fahraeus. 2003. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301: 1371-1374.
13. Brooks, L., Q. Y. Yao, A. B. Rickinson, and L. S. Young. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66: 2689-2697.
14. Heussinger, N., M. Buttner, G. Ott, E. Brachtel, B. Z. Pilch, E. Kremmer, and G. Niedobitek. 2004. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J. Pathol. 203: 696-699.
15. Niedobitek, G., E. Kremmer, H. Herbst, L. Whitehead, C. W. Dawson, E. Niedobitek, C. von Ostau, N. Rooney, F. A. Grasser, and L. S. Young. 1997. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 90: 1664-1672.
16. Whitney, B. M., A. T. Chan, A. B. Rickinson, S. P. Lee, C. K. Lin, and P. J. Johnson. 2002. Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. J. Med. Virol. 67: 359-363.
17. Chapman, A. L., A. B. Rickinson, W. A. Thomas, R. F. Jarrett, J. Crocker, and S. P. Lee. 2001. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res. 61: 6219-6226.
18. Maggio, E., B. A. van den, A. Diepstra, J. Kluiver, L. Visser, and S. Poppema. 2002. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann. Oncol. 13 (Suppl. 1): 52-56.
19. Budiani, D. R., S. Hutahaean, S. M. Haryana, M. H. Soesatyo, and W. Sosroseno. 2002. Interleukin-10 levels in Epstein-Barr virus-associated nasopharyngeal carcinoma. J. Microbiol. Immunol. Infect. 35: 265-268.
20. Marshall, N. A., L. E. Christie, L. R. Munro, D. J. Culligan, P. W. Johnston, R. N. Barker, and M. A. Vickers. 2004. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103: 1755-1762.
21. Duraiswamy, J., M. Bharadwaj, J. Tellam, G. Connolly, L. Cooper, D. Moss, S. Thomson, P. Yotnda, and R. Khanna. 2004. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res. 64: 1483-1489.
22. + T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 62: 6952-6958.
23. Roskrow, M. A., N. Suzuki, Y. Gan, J. W. Sixbey, C. Y. Ng, S. Kimbrough, M. Hudson, M. K. Brenner, H. E. Heslop, and C. M. Rooney. 1998. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91: 2925-2934.
24. Chua, D., J. Huang, B. Zheng, S. Y. Lau, W. Luk, D. L. Kwong, J. S. Sham, D. Moss, K. Y. Yuen, S. W. Im, and M. H. Ng. 2001. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int. J. Cancer 94: 73-80.
25. Straathof, K. C., C. M. Bollard, U. Popat, M. H. Huls, T. Lopez, M. C. Morriss, M. V. Gresik, A. P. Gee, H. V. Russell, M. K. Brenner, et al. 2004. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105: 1898-1904.
26. + Hodgkin's disease. Blood 89: 1978-1986.
27. Lee, S. P., W. A. Thomas, R. J. Murray, F. Khanim, S. Kaur, L. S. Young, M. Rowe, M. Kurilla, and A. B. Rickinson. 1993. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J. Virol. 67: 7428-7435.
28. Lee, S. P., A. T. Chan, S. T. Cheung, W. A. Thomas, D. CroomCarter, C. W. Dawson, C. H. Tsai, S. F. Leung, P. J. Johnson, and D. P. Huang. 2000. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J. Immunol. 165: 573-582.
29. + T-cell epitope in Epstein-Barr virus latent membrane protein 2. J. Virol. 77: 2757-2761.
30. Lee, S. P., R. J. Tierney, W. A. Thomas, J. M. Brooks, and A. B. Rickinson. 1997. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J. Immunol. 158: 3325-3334.
31. Khanna, R., S. R. Burrows, D. J. Moss, and S. L. Silins. 1996. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J. Virol. 70: 5357-5362.
32. Brooks, J. M., R. J. Murray, W. A. Thomas, M. G. Kurilla, and A. B. Rickinson. 1993. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J. Exp. Med. 178: 879-887.
33. + T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int. J. Cancer 99: 93-99.
34. Gottschalk, S., C. Y. Ng, M. Ferez, C. A. Smith, C. Sample, M. K. Brenner, H. E. Heslop, and C. M. Rooney. 2001. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97: 835-843.
35. + Hodgkin's disease. J. Exp. Med. 200: 1623-1633.
36. Smith, C. A., C. Y. Ng, H. E. Heslop, M. S. Holladay, S. Richardson, E. V. Turner, S. K. Loftin, C. Li, M. K. Brenner, and C. M. Rooney. 1995. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J. Hematother. 4: 73-79.
37. +-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J. Virol. 73: 8179-8184.
38. Marsh, S. G. E., P. Parham, and L. D. Barber. 2000. The HLA Factsbook. Academic Press, London, United Kingdom.
39. + T-helper 1 responses. J. Virol. 75: 8649-8659.
40. Abdel-Hamid, M., J. J. Chen, N. Constantine, M. Massoud, and N. Raab-Traub. 1992. EBV strain variation: geographical distribution and relation to disease state. Virology 190: 168-175.
41. Busson, P., R. McCoy, R. Sadler, K. Gilligan, T. Tursz, and N. Raab-Traub. 1992. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J. Virol. 66: 3257-3262.
42. Poppema, S., M. Potters, L. Visser, and A. M. van den Berg. 1998. Immune escape mechanisms in Hodgkin's disease. Ann. Oncol. 9 (Suppl. 5): S21-S24.
43. Chan, A. T., P. M. Teo, and P. J. Johnson. 2002. Nasopharyngeal carcinoma. Ann. Oncol. 13: 1007-1015.
44. Glaser, S. L., R. J. Lin, S. L. Stewart, R. F. Ambinder, R. F. Jarrett, P. Brousset, G. Pallesen, M. L. Gulley, G. Khan, J. O'Grady, et al. 1997. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int. J. Cancer 70: 375-382.
45. Cao, K., J. Hollenbach, X. Shi, W. Shi, M. Chopek, and M. A. Fernandez-Vina. 2001. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum. Immunol. 62: 1009-1030.
46. Craiu, A., T. Akopian, A. Goldberg, and K. L. Rock. 1997. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc. Natl. Acad. Sci. USA 94: 10850-10855.
47. Mo, X. Y., P. Cascio, K. Lemerise, A. L. Goldberg, and K. Rock. 1999. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J. Immunol. 163: 5851-5859.
48. Stoltze, L., T. P. Dick, M. Deeg, B. Pommerl, H. G. Rammensee, and H. Schild. 1998. Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities. Eur. J. Immunol. 28: 4029-4036.
49. Hisamatsu, H., N. Shimbara, Y. Saito, P. Kristensen, K. B. Hendil, T. Fujiwara, E. Takahashi, N. Tanahashi, T. Tamura, A. Ichihara, and K. Tanaka. 1996. Newly identified pair of proteasomal subunits regulated reciprocally by interferon γ. J. Exp. Med. 183: 1807-1816.
50. Nandi, D., H. Jiang, and J. J. Monaco. 1996. Identification of MECL-1 (LMP-10) as the third IFN-γ-inducible proteasome subunit. J. Immunol 156: 2361-2364.
51. Miller, G., J. Robinson, L. Heston, and M. Lipman. 1974. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc. Natl. Acad. Sci. USA 71: 4006-4010.
52. Edwards, R. H., D. Sitki-Green, D. T. Moore, and N. Raab-Traub. 2004. Potential selection of LMP1 variants in nasopharyngeal carcinoma. J. Virol. 78: 868-881.
53. Yee, C., J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg. 2000. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192: 1637-1544.
54. Gottschalk, S., O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney. 2003. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 101: 1905-1912.
55. Bollard, C. M., K. C. Straathof, M. H. Huls, A. Leen, K. Lacuesta, A. Davis, S. Gottschalk, M. K. Brenner, H. E. Heslop, and C. M. Rooney. 2004. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J. Immunother. 27: 317-327.